A Phase 4 interventional study of Entecavir and Adefovir/Entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 8 sites in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-02-11.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 16th largest by enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2008, is one of 33 in phase 4, and was the 17th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 4, and was the 12th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Entecavir
Control
Drug: Adefovir/Entecavir
Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing
HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.
Time frame: At Week 12 from Day 1
Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing
HBV=hepatitis B virus. HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.
Time frame: At Week 48 from Day 1
Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing
HBV=hepatitis B virus
Time frame: At Weeks 12 and 48 from Day 1
Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)
ULN=upper limit of normal. ALT normalization= ≤1\*ULN, among participants with baseline ALT \>1\*ULN
Time frame: At Weeks 12 and 48 from Day 1
Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion
Time frame: At Weeks 12 and 48 from Day 1
Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion
Time frame: At Weeks 12 and 48 from Day 1
Number of Participants With Genotypic Resistance to Entecavir
Time frame: At Week 48 from Day 1
Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.
Time frame: Continually from Day 1 through Week 48, and through 24-week follow-up period
Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results
Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.
Time frame: Day 1 through Week 48
| Milestone | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Started | 89 | 77 |
| Completed | 84 | 68 |
| Not completed | 5 | 9 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Not identified | 2 | 7 |
HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.
| Percentage of participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing | 5.6 | 0.0 |
HBV=hepatitis B virus. HBV DNA Level \<50 IU/mL=approximately 300 copies/mL.
| Percentage of participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing | 31.5 | 28.6 |
HBV=hepatitis B virus
| log10 IU/mL | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Week 12 (n=88, 77) | -2.5 ± 1.2 | -0.2 ± 1.1 |
| Week 48 (n=87, 71) | -3.3 ± 1.5 | -3.2 ± 1.3 |
ULN=upper limit of normal. ALT normalization= ≤1\*ULN, among participants with baseline ALT \>1\*ULN
| Percentage of participants | Entecavir, 0.5 mg QD | Adeforvi, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Week 12 (n=51, 36) | 31.4 | 22.2 |
| Week 48 (n=51, 36) | 60.8 | 47.2 |
| Percentage of participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 10 mg QD |
|---|---|---|
| HBeAG loss Week 12 (n=79, 72) | 3.8 | 6.9 |
| HBeAG loss Week 48 (n=79, 72) | 7.6 | 6.9 |
| HBe seroconversion Week 12 (n=79, 72) | 2.5 | 1.45 |
| HBe seroconversion Week 48 (n=79, 72) | 3.8 | 2.8 |
| Participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Week 12 HBsAg loss | 0 | 0 |
| Week 48 HBsAg loss | 0 | 0 |
| Week 12 HBsAg seroconversion | 0 | 0 |
| Week 48 HBsAg seroconversion | 0 | 0 |
| Participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| At baseline | 0 | 0 |
| Week 48 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.
| Participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| All AEs | 16 | 7 |
| Treatment-related AEs | 0 | 0 |
| SAEs | 1 | 0 |
| Treatment-related SAEs | 0 | 0 |
| Death | 0 | 0 |
| AEs leading to discontinuation | 1 | 0 |
| Abnormalities in LTR leading to discontinuation | 0 | 0 |
Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.
| Percentage of participants | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD |
|---|---|---|
| Alanine aminotransferase | 9 | 5.2 |
| Aspartate aminotransferase | 2.2 | 0 |
| Hyperkalemia | 0 | 1 |
| Hematology | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entecavir, 0.5 mg QD | — | 1/89 (1.1%) | 8/89 (9%) |
| Adefovir, 10 mg QD/Entecavir, 0.5 mg QD | — | 0/77 (0%) | 9/77 (11.7%) |
| Event | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Drug hepatitisHepatobiliary disorders | 1/89 | 0/77 |
| Event | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 8/89 | 9/77 |
| Aspartate aminotransferase increasedInvestigations | 5/89 | 0/77 |
| Age Continuous(Years) | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD | Total |
|---|---|---|---|
| Median | 32.6 (16.9 to 62.4) | 34.1 (18.9 to 63.1) | 33.4 (16.9 to 63.1) |
| Sex: Female, Male(Participants) | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD | Total |
|---|---|---|---|
| Female | 14 | 10 | 24 |
| Male | 75 | 67 | 142 |
| Race/Ethnicity, Customized(Participants) | Entecavir, 0.5 mg QD | Adefovir, 10 mg QD/Entecavir, 0.5 mg QD | Total |
|---|---|---|---|
| Asian | 89 | 77 | 166 |
| Other | 0 | 0 | 0 |
The record gives a start of Jul 2008, a primary completion of Dec 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir